[go: up one dir, main page]

NO20091580L - Behandling av infant-hyperbilirubinemi ved anvendelse av lave doser stannsoporfin - Google Patents

Behandling av infant-hyperbilirubinemi ved anvendelse av lave doser stannsoporfin

Info

Publication number
NO20091580L
NO20091580L NO20091580A NO20091580A NO20091580L NO 20091580 L NO20091580 L NO 20091580L NO 20091580 A NO20091580 A NO 20091580A NO 20091580 A NO20091580 A NO 20091580A NO 20091580 L NO20091580 L NO 20091580L
Authority
NO
Norway
Prior art keywords
treatment
hyperbilirubinaemia
infant
stansoporphine
low doses
Prior art date
Application number
NO20091580A
Other languages
English (en)
Inventor
Benjamin Levinson
Simon Tulloch
Original Assignee
Infacare Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infacare Pharmaceutical Corp filed Critical Infacare Pharmaceutical Corp
Publication of NO20091580L publication Critical patent/NO20091580L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives fremgangsmåter for behandling av infant hyperbilirubinemi ved bruk av stannsoporfin. Oppfinnelsens fremgangsmåter tillater behandling av forskjellige pasientpopulasjoner ved lavere doser av stannsoporfin enn det som tidligere var antatt effektivt, noe som gir fordeler ved den terapeutiske administrering.
NO20091580A 2006-10-04 2009-04-21 Behandling av infant-hyperbilirubinemi ved anvendelse av lave doser stannsoporfin NO20091580L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84950906P 2006-10-04 2006-10-04
PCT/US2007/021486 WO2008045378A2 (en) 2006-10-04 2007-10-04 Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin

Publications (1)

Publication Number Publication Date
NO20091580L true NO20091580L (no) 2009-05-04

Family

ID=39036883

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091580A NO20091580L (no) 2006-10-04 2009-04-21 Behandling av infant-hyperbilirubinemi ved anvendelse av lave doser stannsoporfin

Country Status (13)

Country Link
US (1) US20080113955A1 (no)
EP (1) EP2076273A2 (no)
JP (1) JP2010505854A (no)
KR (1) KR20090079916A (no)
CN (1) CN101631554A (no)
AU (1) AU2007307112A1 (no)
BR (1) BRPI0717774A2 (no)
CA (1) CA2664934A1 (no)
EA (1) EA200970345A1 (no)
IL (1) IL197839A0 (no)
MX (1) MX2009003532A (no)
NO (1) NO20091580L (no)
WO (1) WO2008045378A2 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375216B2 (en) 2002-06-04 2008-05-20 Infacare Pharmaceutical Corporation Preparation of metal mesoporphyrin compounds
US20060222668A1 (en) * 2005-04-01 2006-10-05 Wellspring Pharmaceutical Corporation Stannsoporfin compositions, drug products and methods of manufacture
CN101573122B (zh) 2006-10-04 2016-08-03 婴儿护理药品公司 锡泊芬的高纯度大规模制备
US20090293326A1 (en) * 2008-05-29 2009-12-03 Bedford Nieves-Cruz Hyperbilirubinemia management calendar
RU2414879C2 (ru) * 2009-01-11 2011-03-27 Николай Федосеевич Давыдкин Способ лечения гипербилирубинемии новорожденных
RU2389499C1 (ru) * 2009-02-10 2010-05-20 Иван Ильич Таранов Способ лечения больных с гипербилирубинемией
US8735574B2 (en) 2011-03-30 2014-05-27 Infacare Pharmaceutical Corporation Methods for synthesizing metal mesoporphyrins
US20130158362A1 (en) * 2011-12-01 2013-06-20 Infacare Pharmaceutical Corporation Methods for treating hyperbilirubinemia with stannsoporfin
WO2017197249A2 (en) * 2016-05-12 2017-11-16 Infacare Pharmaceutical Corporation Methods for treating hyperbilirubinemia with stannsoporfin and phototherapycross-reference to related applications
WO2021126855A1 (en) * 2019-12-16 2021-06-24 Mallinckrodt Hospital Products IP Unlimited Company Methods for treating progressive hyperbilirubinemia

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708964A (en) * 1984-02-09 1987-11-24 Chemex Pharmaceuticals Lipoxygenase inhibitors
US4861876A (en) * 1986-11-26 1989-08-29 Wayne State University Hematoporphyrin derivative and method of preparation and purification
US5990363A (en) * 1987-01-02 1999-11-23 Sun Company, Inc. Method for oxidizing alkanes using novel porphyrins synthesized from dipyrromethanes and aldehydes
US4900871A (en) * 1987-01-02 1990-02-13 Sun Refining And Marketing Company Hydrocarbon oxidations catalyzed by iron coordination complexes containing a halogenated ligand
US5062775A (en) * 1989-09-29 1991-11-05 Rocky Mountain Research, Inc. Roller pump in an extra corporeal support system
US5192757A (en) * 1990-12-20 1993-03-09 Glaxo Inc. Cobalt porphyrins
US5371199B1 (en) * 1992-08-14 1995-12-26 Univ Pennsylvania Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor
US5493017A (en) * 1992-08-14 1996-02-20 The Trustees Of The University Of Pennsylvania Ring-metalated porphyrins
US5817830A (en) * 1992-08-14 1998-10-06 Trustees Of The University Of Pennsylvania Pyrrolic compounds
AU7103594A (en) * 1993-06-14 1995-01-03 Rockefeller University, The Treatment of neonatal hyperbilirubin with metalloporphyrin
CA2130853A1 (en) * 1994-08-25 1996-02-26 Svetlana Kudrevich Process for the syntheses of monosulphonated phthalocyanines, naphthobenzoporphyrazines and porphyrins via a modified meerwein reaction
US5912341A (en) * 1995-03-14 1999-06-15 Hoffman/Barrett, L.L.C. Heteroatom-functionalized porphyrazines and multimetallic complexes and polymers derived therefrom
AU6497996A (en) * 1995-08-02 1997-02-26 Warner-Lambert Company Amino acid complexes of cobalt (iii) mesoporphyrin ix and cobalt (iii) protoporphyrin ix
US5883246A (en) * 1996-03-07 1999-03-16 Qlt Phototherapeutics, Inc. Synthesis of polypyrrolic macrocycles from meso-substituted tripyrrane compounds
US6004530A (en) * 1996-06-04 1999-12-21 Roche Diagnostics Gmbh Use of metallo-porphyrin conjugates for the detection of biological substances
GB9616353D0 (en) * 1996-08-03 1996-09-11 Secr Defence Metallo-porphyrins
US6124452A (en) * 1997-12-19 2000-09-26 University Of Nebraska-Lincoln Octafluoro-meso-tetraarylporphyrins and methods for making these compounds
DE19706490C1 (de) * 1997-02-19 1998-09-17 Deutsches Krebsforsch Verfahren zur Herstellung von Säureamiden und zur Metallierung von Verbindungen und Verwendung der nach den Verfahren hergestellten Verbindungen
US5886173A (en) * 1997-07-30 1999-03-23 Pharmacyclics, Inc. Metallation of macrocycles with 2,4-dicarbonyl-metal complexes
US6194566B1 (en) * 1997-12-02 2001-02-27 Schering Aktiengesellschaft Process for the production of metalloporphyrin-metal complex conjugates
JP3673888B2 (ja) * 1998-03-09 2005-07-20 独立行政法人科学技術振興機構 ポルフィリン類金属錯体の製造方法
DE19831217A1 (de) * 1998-07-03 2000-01-05 Schering Ag Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
US5973141A (en) * 1998-11-27 1999-10-26 Miravant Pharmaceuticals, Inc. Method for the demethoxycarbonylation of porphyrinic compounds such as pheophorbides
US6462192B2 (en) * 2001-01-23 2002-10-08 Miravant Pharmaceuticals, Inc. Processes for large scale production of tetrapyrroles
US6906050B2 (en) * 2001-05-31 2005-06-14 Miravant Pharmaceuticals, Inc. Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and MRI diagnosis
CA2487426C (en) * 2002-06-04 2010-09-07 Wellspring Pharmaceutical Corporation Preparation of metal mesoporphyrin halide compounds
US7375216B2 (en) * 2002-06-04 2008-05-20 Infacare Pharmaceutical Corporation Preparation of metal mesoporphyrin compounds
US20040097481A1 (en) * 2002-11-20 2004-05-20 Benjamin Levinson Water-soluble mesoporphyrin compounds and methods of preparation
US20060222668A1 (en) * 2005-04-01 2006-10-05 Wellspring Pharmaceutical Corporation Stannsoporfin compositions, drug products and methods of manufacture

Also Published As

Publication number Publication date
CA2664934A1 (en) 2008-04-17
BRPI0717774A2 (pt) 2014-04-29
EA200970345A1 (ru) 2009-10-30
MX2009003532A (es) 2009-06-26
WO2008045378A3 (en) 2008-06-05
US20080113955A1 (en) 2008-05-15
CN101631554A (zh) 2010-01-20
KR20090079916A (ko) 2009-07-22
EP2076273A2 (en) 2009-07-08
IL197839A0 (en) 2009-12-24
WO2008045378A2 (en) 2008-04-17
AU2007307112A1 (en) 2008-04-17
JP2010505854A (ja) 2010-02-25

Similar Documents

Publication Publication Date Title
NO20091580L (no) Behandling av infant-hyperbilirubinemi ved anvendelse av lave doser stannsoporfin
MX2009011533A (es) Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas.
PH12014500386A1 (en) Combination treatment for hepatitis c
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MA32568B1 (fr) Formulations pharmaceutiques contenant des ligands de recepteur de dopamine
NZ707377A (en) Combination therapy methods for treating proliferative diseases
MX2014002668A (es) Tratamiento de enfermedades relacionadas con subunidades alfa de canales de sonido regulados por voltaje (scnxa) con moleculas pequeñas.
IL201479A (en) Use of tapentadol for the preparation of pain medication
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MX2009012598A (es) Formas de dosis que comprenden vx-950 y su regimen de dosificacion.
EA201290808A1 (ru) Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
PH12013500559A1 (en) Combination therapy for treating hcv infection
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
EA201390417A1 (ru) Антидиабетические твердые фармацевтические композиции
MX2015005993A (es) Composiciones y metodos para el tratamiento de displasia ectodermica.
EA201390925A1 (ru) Производные санглиферина и способы их получения
TR200900880A2 (tr) Tek bir dozaj formunda kombine edilen farmasötik bileşimler.
TN2013000134A1 (en) Combination therapy for treating hcv infection
UA48591U (ru) Способ лечения разлитых флегмон челюстно-лицевого участка

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application